Change institution

Michael Doubek

Email: ,
Phone: +420 532 232 144, +420 532 233 603
Research Group: Medical Genomics - Šárka Pospíšilová

2017

  • KOTASKOVA, J; PAVLOVA, S; PLEVOVA, K; MALCIKOVA, J; STEHLIKOVA, O; POPPOVA, L; KOCKOVA, H; DOUBEK, M; BRYJA, V; POSPISILOVA, S, 2017:TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS. HAEMATOLOGICA 102 , p. 414 - 414.
  • LEDEREROVA, A; KOZLOVA, V; VAKULOVA, V; DOUBEK, M; MAYER, J; POSPISILOVA, S; SMIDA, M, 2017:B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE. HAEMATOLOGICA 102 , p. 709 - 709.
  • PAVLASOVA, G; BORSKY, M; SVOBODOVA, V; MUSILOVA, K; CERNA, K; SEDA, V; OSICKOVA, J; BRYCHTOVA, Y; DOUBEK, M; POSPISILOVA, S; MAYER, J; MRAZ, M, 2017:BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO. HAEMATOLOGICA 102 , p. 412 - 412.
  • PLEVOVA, K; MALCIKOVA, J; PAVLOVA, S; KOTASKOVA, J; POPPOVA, L; SMARDOVA, J; DIVISKOVA, E; DURECHOVA, K; OLTOVA, A; BRYCHTOVA, Y; PANOVSKA, A; DOUBEK, M; POSPISILOVA, S, 2017:BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY. HAEMATOLOGICA 102 , p. 65 - 66.

2016

  • KUBESOVA, B; PAVLOVA, S; MALCIKOVA, J; KABATHOVA, J; RADOVA, L; TOM, N; TICHY, B; PLEVOVA, K; KANTOROVA, B; FIEDOROVA, K; KISSOVA, J; GISSLINGER, B; GISSLINGER, H; MAYER, J; KRALOVICS, R; POSPISILOVA, S; DOUBEK, M, 2016:Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128 (22)
  • POPPOVA, L; JANOVSKA, P; PLEVOVA, K; RADOVA, L; PLESINGEROVA, H; BORSKY, M; KOTASKOVA, J; KANTOROVA, B; HLOZKOVA, M; FIGULOVA, J; BRYCHTOVA, Y; DOUBEK, M; KOZUBIK, A; POSPISILOVA, S; PAVLOVA, S; BRYJA, V, 2016:DECREASED EXPRESSION OF WNT3, A CANONICAL WNT PATHWAY LIGAND, IS FREQUENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION AND IDENTIFIES PATIENTS WITH SHORT TREATMENT-FREE SURVIVAL IN MUTATED IGHV SUBSET. HAEMATOLOGICA 101 , p. 423 - 424.
Office 1:
Masarykova univerzita - CEITEC MU
More CEITEC News ...
Dr. Ondrej Hovorka: Models of magnetic nanoparticles for biomedical applications

29. ledna 2018 9:46

Dr. Ondrej Hovorka: Models of magnetic nanoparticles for biomedical…

LECTURE: Dr. Ondrej Hovorka: Models of magnetic nanoparticles for biomedical applications

Advanced Materials and Nanotechnology Seminar Series 2018: Dr Andriy Marko

25. ledna 2018 18:21

Advanced Materials and Nanotechnology Seminar Series 2018: Dr Andriy…

WHEN: 30. 01. 2018 WHERE: CEITEC BUT, Purkynova 123, large meeting room SPEAKER: Dr Andriy Marko TALK: Advances in PELDOR…